AACR: Pretrained Machine Learning Models Help Diagnose Nonmelanoma Skin Cancer
By Elana Gotkine HealthDay Reporter
TUESDAY, April 29, 2025 -- Leveraging whole slide embedding from pretrained foundation models (FMs) improves nonmelanoma skin cancer (NMSC) diagnosis, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 25 to 30 in Chicago.
Spencer Ellis, from the University of Chicago, and colleagues examined the effectiveness of general purpose FMs for diagnosis of NMSC, specifically in resource-constrained environments. Three pathology FMs (UNI, PRISM, and Prov-GigaPath) were evaluated, as was a ResNet18 baseline model. Data were included for 2,130 whole-slide images from 553 suspected NMSC biopsy samples from 455 participants: 706 normal tissue; 638 Bowen disease; 575 basal cell carcinoma; and 211 invasive squamous cell carcinoma.
The researchers found that all three FMs significantly outperformed ResNet18 (mean area under the receiver operating characteristic curve [AUROC], 0.805). The overall best model used the PRISM tile embeddings aggregated using PRISM's intrinsic Perceiver network, which trained a multilayer perceptron (MLP) model to predict the subtype of NMSC (AUROC, 0.925). Using attention-based multi-instance learning to aggregate tile embeddings to train an MLP model was optimal for the UNI and Prov-GigaPath models (mean AUROCs, 0.913 and 0.908, respectively). The simplest method with logistic regression of global average pooling aggregated embeddings could attain reasonable results for PRISM, UNI, and Prov-GigaPath (mean AUROCs, 0.882, 0.865, and 0.855, respectively).
"Our results demonstrate that pretrained machine learning models have the potential to aid diagnosis of NMSC, which might be particularly beneficial in resource-limited settings," coauthor Steven Song, from the Pritzker School of Medicine at the University of Chicago, said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Melphalan/Hepatic Delivery System Beneficial for Metastatic Uveal Melanoma
THURSDAY, April 24, 2025 -- For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and...
Circulating Tumor DNA Can ID Outcomes for Patients With Melanoma
WEDNESDAY, April 16, 2025 -- Droplet digital polymerase chain reaction (PCR) measurements of cell-free, circulating tumor DNA (ctDNA) can identify patients with melanoma and a...
Common Photosensitizing Drugs Increase Skin Cancer Risk
TUESDAY, April 1, 2025 -- Some commonly prescribed photosensitizing drugs increase skin cancer risk, according to a study published online March 18 in Photodermatology...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.